NCCN VERSION 2 2015

172 / 188

Version 2.2015, 03/11/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. MS-97
NCCN Guidelines Index
Breast Cancer Table of Contents
Discussion
NCCN Guidelines Version 2.2015
Breast Cancer
413. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a
cytokine that regulates osteoclast differentiation and activation. Cell
1998;93:165-176. Available at:
414. Woo S-B, Hellstein JW, Kalmar JR. Narrative [corrected] review:
bisphosphonates and osteonecrosis of the jaws. Ann Intern Med
2006;144:753-761. Available at:
.
415. Ali SM, Esteva FJ, Hortobagyi G, et al. Safety and efficacy of
bisphosphonates beyond 24 months in cancer patients. J Clin Oncol
2001;19:3434-3437. Available at:
.
416. Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces
skeletal-related events in patients with osteolytic metastases. Cancer
2001;91:1191-1200. Available at:
.
417. Conte PF, Latreille J, Mauriac L, et al. Delay in progression of
bone metastases in breast cancer patients treated with intravenous
pamidronate: results from a multinational randomized controlled trial.
The Aredia Multinational Cooperative Group. J Clin Oncol
1996;14:2552-2559. Available at:
418. Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention
of skeletal complications of metastatic breast cancer with pamidronate.
Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol
1998;16:2038-2044. Available at:
419. Theriault RL. The role of bisphosphonates in breast cancer. J Natl
Compr Canc Netw 2003;1:232-241. Available at:
.
420. Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces
skeletal morbidity in women with advanced breast cancer and lytic bone
lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia
Breast Cancer Study Group. J Clin Oncol 1999;17:846-854. Available
at:
421. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus
pamidronate in the treatment of skeletal metastases in patients with
breast cancer or osteolytic lesions of multiple myeloma: a phase III,
double-blind, comparative trial. Cancer J 2001;7:377-387. Available at:
.
422. Rosen LS, Gordon DH, Dugan W, et al. Zoledronic acid is superior
to pamidronate for the treatment of bone metastases in breast
carcinoma patients with at least one osteolytic lesion. Cancer
2004;100:36-43. Available at:
.
423. Diel IJ, Body JJ, Lichinitser MR, et al. Improved quality of life after
long-term treatment with the bisphosphonate ibandronate in patients
with metastatic bone disease due to breast cancer. Eur J Cancer
2004;40:1704-1712. Available at:
.
424. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of
pamidronate in reducing skeletal complications in patients with breast
cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer
Study Group. N Engl J Med 1996;335:1785-1791. Available at:
425. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents
skeletal complications and is effective palliative treatment in women
with breast carcinoma and osteolytic bone metastases: long term follow-
up of two randomized, placebo-controlled trials. Cancer 2000;88:1082-
1090. Available at:
426. McLachlan SA, Cameron D, Murray R, et al. Safety of oral
ibandronate in the treatment of bone metastases from breast cancer :